O	0	2	No	No	DT	B-NP
O	3	11	evidence	evidence	NN	I-NP
O	12	15	for	for	IN	B-PP
O	16	18	an	an	DT	B-NP
O	19	28	influence	influence	NN	I-NP
O	29	31	of	of	IN	B-PP
O	32	35	the	the	DT	B-NP
O	36	41	human	human	JJ	I-NP
O	42	50	platelet	platelet	NN	I-NP
O	51	58	antigen	antigen	NN	I-NP
O	58	59	-	-	HYPH	B-NP
O	59	60	1	1	CD	I-NP
O	61	73	polymorphism	polymorphism	NN	I-NP
O	74	76	on	on	IN	B-PP
O	77	80	the	the	DT	B-NP
O	81	93	antiplatelet	antiplatelet	JJ	I-NP
O	94	101	effects	effect	NNS	I-NP
O	102	104	of	of	IN	B-PP
O	105	117	glycoprotein	glycoprotein	NN	B-NP
O	118	121	IIb	IIb	NN	I-NP
O	121	122	/	/	SYM	B-NP
O	122	126	IIIa	IIIa	NN	I-NP
O	127	137	inhibitors	inhibitor	NNS	I-NP
O	137	138	.	.	.	O

O	139	143	This	This	DT	B-NP
O	144	149	study	study	NN	I-NP
O	150	162	investigated	investigate	VBD	B-VP
O	163	166	the	the	DT	B-NP
O	167	177	hypothesis	hypothesis	NN	I-NP
O	178	182	that	that	IN	B-SBAR
O	183	186	the	the	DT	B-NP
O	187	192	human	human	JJ	I-NP
O	193	201	platelet	platelet	NN	I-NP
O	202	209	antigen	antigen	NN	I-NP
O	209	210	-	-	HYPH	B-NP
O	210	211	1	1	CD	I-NP
O	212	213	(	(	(	O
O	213	216	HPA	HPA	NN	O
O	216	217	-	-	HYPH	O
O	217	218	1	1	CD	O
O	218	219	)	)	)	O
O	220	232	polymorphism	polymorphism	NN	B-NP
O	233	236	may	may	MD	B-VP
O	237	246	influence	influence	VB	I-VP
O	247	250	the	the	DT	B-NP
O	251	263	antiplatelet	antiplatelet	JJ	I-NP
O	264	271	effects	effect	NNS	I-NP
O	272	274	of	of	IN	B-PP
O	275	287	glycoprotein	glycoprotein	NN	B-NP
O	288	289	(	(	(	O
O	289	291	GP	GP	NN	B-NP
O	291	292	)	)	)	O
O	292	295	IIb	IIb	NN	B-NP
O	295	296	/	/	SYM	B-NP
O	296	300	IIIa	IIIa	NN	I-NP
O	301	311	inhibitors	inhibitor	NNS	I-NP
O	311	312	.	.	.	O

O	313	322	Adenosine	Adenosine	NN	B-NP
O	323	334	diphosphate	diphosphate	NN	I-NP
O	335	336	(	(	(	O
O	336	338	30	30	CD	B-NP
O	339	344	micro	micro	NN	I-NP
O	345	348	mol	mol	NN	I-NP
O	348	349	)	)	)	O
O	349	350	-	-	HYPH	B-NP
O	350	357	induced	induce	VBN	I-NP
O	358	368	fibrinogen	fibrinogen	NN	I-NP
O	369	376	binding	binding	NN	I-NP
O	377	380	was	be	VBD	B-VP
O	381	389	measured	measure	VBN	I-VP
O	390	392	by	by	IN	B-PP
O	393	397	flow	flow	NN	B-NP
O	398	407	cytometry	cytometry	NN	I-NP
O	407	408	.	.	.	O

O	409	418	Abciximab	Abciximab	NN	B-NP
O	419	420	(	(	(	O
O	420	421	0	0	CD	B-NP
O	421	422	.	.	.	O
O	422	424	03	03	CD	B-NP
O	424	425	-	-	HYPH	I-NP
O	425	426	3	3	CD	I-NP
O	427	432	micro	micro	NN	I-NP
O	433	434	g	g	NN	I-NP
O	434	435	/	/	SYM	B-NP
O	435	437	ml	ml	NN	I-NP
O	437	438	)	)	)	O
O	438	439	,	,	,	O
O	440	449	tirofiban	tirofiban	NN	B-NP
O	450	451	(	(	(	O
O	451	452	0	0	CD	B-NP
O	452	453	.	.	.	O
O	453	454	3	3	CD	B-NP
O	454	455	-	-	HYPH	I-NP
O	455	457	30	30	CD	I-NP
O	458	462	nmol	nmol	NN	I-NP
O	462	463	/	/	SYM	B-NP
O	463	464	l	l	NN	I-NP
O	464	465	)	)	)	O
O	466	468	or	or	CC	O
O	469	481	eptifibatide	eptifibatide	NN	B-NP
O	482	483	(	(	(	O
O	483	484	0	0	CD	B-NP
O	484	485	.	.	.	O
O	485	487	01	01	CD	B-NP
O	487	488	-	-	HYPH	I-NP
O	488	489	1	1	CD	I-NP
O	490	495	micro	micro	NN	I-NP
O	496	497	g	g	NN	I-NP
O	497	498	/	/	SYM	B-NP
O	498	500	ml	ml	NN	I-NP
O	500	501	)	)	)	O
O	502	506	were	be	VBD	B-VP
O	507	516	incubated	incubate	VBN	I-VP
O	517	520	for	for	IN	B-PP
O	521	523	15	15	CD	B-NP
O	524	527	min	min	NN	I-NP
O	528	532	with	with	IN	B-PP
O	533	536	the	the	DT	B-NP
O	537	544	samples	sample	NNS	I-NP
O	545	550	prior	prior	RB	B-ADVP
O	551	553	to	to	TO	B-PP
O	554	565	stimulation	stimulation	NN	B-NP
O	565	566	.	.	.	O

O	567	569	IC	IC	NN	B-NP
O	569	570	(	(	(	O
O	570	572	50	50	CD	B-NP
O	572	573	)	)	)	O
O	574	580	values	value	NNS	B-NP
O	581	584	for	for	IN	B-PP
O	585	588	the	the	DT	B-NP
O	589	599	inhibition	inhibition	NN	I-NP
O	600	602	of	of	IN	B-PP
O	603	613	fibrinogen	fibrinogen	NN	B-NP
O	614	621	binding	binding	NN	I-NP
O	622	626	were	be	VBD	B-VP
O	627	637	determined	determine	VBN	I-VP
O	638	642	from	from	IN	B-PP
O	643	647	each	each	DT	B-NP
O	648	658	experiment	experiment	NN	I-NP
O	658	659	.	.	.	O

O	660	663	All	All	DT	B-NP
O	664	672	subjects	subject	NNS	I-NP
O	673	677	were	be	VBD	B-VP
O	678	687	genotyped	genotype	VBN	I-VP
O	688	690	by	by	IN	B-PP
O	691	697	GALIOS	GALIOS	NN	B-NP
O	698	701	and	and	CC	O
O	702	711	automated	automate	VBD	B-VP
O	712	724	fluorescence	fluorescence	NN	B-NP
O	725	736	correlation	correlation	NN	I-NP
O	737	749	spectroscopy	spectroscopy	NN	I-NP
O	749	750	.	.	.	O

O	751	759	Although	Although	IN	B-SBAR
O	760	761	a	a	DT	B-NP
O	762	768	marked	marked	JJ	I-NP
O	769	780	variability	variability	NN	I-NP
O	781	783	in	in	IN	B-PP
O	784	787	the	the	DT	B-NP
O	788	798	inhibitory	inhibitory	JJ	I-NP
O	799	806	effects	effect	NNS	I-NP
O	807	809	of	of	IN	B-PP
O	810	813	all	all	DT	B-NP
O	814	819	three	three	CD	I-NP
O	820	825	GPIIb	GPIIb	NN	I-NP
O	825	826	/	/	SYM	I-NP
O	826	830	IIIa	IIIa	NN	I-NP
O	831	841	inhibitors	inhibitor	NNS	I-NP
O	842	845	was	be	VBD	B-VP
O	846	855	confirmed	confirm	VBN	I-VP
O	855	856	,	,	,	O
O	857	862	there	there	EX	B-NP
O	863	867	were	be	VBD	B-VP
O	868	870	no	no	DT	B-NP
O	871	882	significant	significant	JJ	I-NP
O	883	894	differences	difference	NNS	I-NP
O	895	902	between	between	IN	B-PP
O	903	906	the	the	DT	B-NP
O	907	916	genotypes	genotype	NNS	I-NP
O	917	921	with	with	IN	B-PP
O	922	929	respect	respect	NN	B-NP
O	930	932	to	to	TO	B-PP
O	933	936	the	the	DT	B-NP
O	937	947	inhibition	inhibition	NN	I-NP
O	948	950	of	of	IN	B-PP
O	951	961	fibrinogen	fibrinogen	NN	B-NP
O	962	969	binding	binding	NN	I-NP
O	969	970	.	.	.	O

O	971	975	Thus	Thus	RB	B-ADVP
O	975	976	,	,	,	O
O	977	980	the	the	DT	B-NP
O	981	988	present	present	JJ	I-NP
O	989	994	study	study	NN	I-NP
O	995	999	does	do	VBZ	B-VP
O	1000	1003	not	not	RB	I-VP
O	1004	1011	provide	provide	VB	I-VP
O	1012	1020	evidence	evidence	NN	B-NP
O	1021	1024	for	for	IN	B-PP
O	1025	1027	an	an	DT	B-NP
O	1028	1034	effect	effect	NN	I-NP
O	1035	1037	of	of	IN	B-PP
O	1038	1041	HPA	HPA	NN	B-NP
O	1041	1042	-	-	HYPH	B-NP
O	1042	1043	1	1	CD	I-NP
O	1044	1056	polymorphism	polymorphism	NN	I-NP
O	1057	1059	on	on	IN	B-PP
O	1060	1063	the	the	DT	B-NP
O	1064	1069	inter	inter	AFX	I-NP
O	1069	1070	-	-	HYPH	I-NP
O	1070	1080	individual	individual	JJ	I-NP
O	1081	1092	variability	variability	NN	I-NP
O	1093	1095	in	in	IN	B-PP
O	1096	1099	the	the	DT	B-NP
B-Cell	1100	1108	platelet	platelet	NN	I-NP
O	1109	1119	inhibitory	inhibitory	JJ	I-NP
O	1120	1127	effects	effect	NNS	I-NP
O	1128	1130	of	of	IN	B-PP
O	1131	1134	the	the	DT	B-NP
O	1135	1140	three	three	CD	I-NP
O	1141	1146	GPIIb	GPIIb	NN	I-NP
O	1146	1147	/	/	SYM	I-NP
O	1147	1151	IIIa	IIIa	NN	I-NP
O	1152	1162	inhibitors	inhibitor	NNS	I-NP
O	1163	1171	approved	approve	VBN	B-VP
O	1172	1175	for	for	IN	B-PP
O	1176	1184	clinical	clinical	JJ	B-NP
O	1185	1188	use	use	NN	I-NP
O	1188	1189	.	.	.	O

